Table 3

Adjusted OR/HR of safety and efficacy outcomes in different treatment groups

OutcomesGroupsAdjusted OR/HR (95% CI)P value
sICHNon-APTRef
SAPT0.185 (0.012 to 2.859)0.227
DAPT17.44 (0.519 to 586.332)0.111
Total APT0.781 (0.103 to 5.944)0.811
Successful recanalisation (mTICI 2b/3)Non-APTRef
SAPT1.883 (0.503 to 7.044)0.347
DAPT0.531 (0.055 to 5.090)0.583
Total APT1.410 (0.452 to 4.396)0.554
Complete recanalisation (mTICI 3)Non-APTRef
SAPT2.586 (1.002 to 6.674)0.05
DAPT0.396 (0.115 to 1.363)0.142
Total APT1.384 (0.628 to 3.053)0.42
Primary outcome: mRS score at 90 daysNon-APTRef
SAPT0.750 (0.0543 to 1.035)0.080
DAPT1.662 (1.048 to 2.638)0.031
Total APT0.976 (0.740 to 1.287)0.864
mRS 0–1Non-APTRef
SAPT1.887 (0.806 to 4.417)0.143
DAPT5.405 (1.614 to 18.102)0.006
Total APT2.605 (1.244 to 5.455)0.011
mRS 0–2Non-APTRef
SAPT1.127 (0.469 to 2.708)0.790
DAPT2.397 (0.690 to 8.330)0.169
Total APT1.418 (0.661 to 3.041)0.369
mRS 6Non-APTRef
SAPT1.159 (0.290 to 4.634)0.835
DAPT0.008 (0.000 to 0.441)0.019
Total APT0.514 (0.147 to 1.797)0.297
  • Adjusted for sex, systolic blood pressure, NIHSS, ASPECTS, atrial fibrillation, hypertension, smoking, other aetiology of TOAST classification, MCA M2/3 segment occlusion site, intravenous thrombolysis, tirofiban, heparin use during, puncture to recanalisation, general anaesthesia, mechanical aspiration and intra-arterial thrombolysis and balloon angioplasty.

  • aICH, asymptomatic intracranial haemorrhage; APT, antiplatelet; ASPECTS, Alberta Stroke Program Early CT Score; DAPT, dual antiplatelet; MCA, middle cerebral artery; mRS, modified Rankin score; mTICI, modified treatment in cerebral infarction; NIHSS, National Institutes of Health Stroke Scale; SAPT, single antiplatelet; sICH, symptomatic intracranial haemorrhage.